Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Botta G, Abdelrahim M, Drengler R, Aushev V, Esmail A, Laliotis G, Brewer C, George G, Abbate S, Chandana S, Tejani M, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi P, Kasi A, Dayyani F, Hanna D, Sharma S, Malhotra M, Aleshin A, Liu M, Jurdi A. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. The Oncologist 2024, 29: 859-869. PMID: 39022993, PMCID: PMC11449101, DOI: 10.1093/oncolo/oyae155.Peer-Reviewed Original ResearchMolecular residual diseasePancreatic ductal adenocarcinomaPatient survival outcomesCtDNA detectionSurvival outcomesStage I–III pancreatic ductal adenocarcinomaAssociated with shorter DFSMedian follow-up timeFollow-up timeCtDNA levelsResidual diseaseShorter DFSPrognostic factorsPancreatic adenocarcinomaAssociated with patient survival outcomesDuctal adenocarcinomaRetrospective analysisDiagnosed patientsMultivariate analysisSurveillance periodPatientsPlasma samplesTumor informationWhole exomeSurveillance windowAbstract B026: Detection and characterization of DDR reversion alterations in baseline tissue and plasma samples from patients enrolled in the TRESR and ATTACC Phase I clinical trials
Silverman I, Schonhoft J, Jain E, Ulanet D, Yang J, Kim I, Fei K, Lagow E, Yablonovitch A, Cecchini M, Rosen E, Lee E, Lheureux S, Yap T, Fontana E, Koehler M, Rimkunas V. Abstract B026: Detection and characterization of DDR reversion alterations in baseline tissue and plasma samples from patients enrolled in the TRESR and ATTACC Phase I clinical trials. Cancer Research 2024, 84: b026-b026. DOI: 10.1158/1538-7445.dnarepair24-b026.Peer-Reviewed Original ResearchPoly(ADP-ribose) polymerase inhibitorsPhase I clinical trialDNA damage repairReversible alterationsECOG PS 0-1Baseline tissuePlatinum-based therapyPlasma samplesInterpretation of efficacy dataHRD-related genesDamage repairDDR alterationsTumor biopsiesOvarian cancerSingle nucleotide variantsWhole-genome sequencingDiagnostic challengeSolid tumorsClinical developmentEvaluate safetyEfficacy dataPolymerase inhibitorsTumorAtaxia telangiectasiaPatients